Hongyu Chu

Nov 28, 2024 | onlinelibrary.wiley.com | Zongyu Liu |Hongyu Chu |Weidong Zhao |Chenguang Yang

1 Introduction Opdivo (nivolumab) plus Yervoy (ipilimumab) is dual immunotherapy targeting and blocking the immune checkpoints PD1 and CTLA-4, and has been successfully applied in clinical cancer therapy,[1] including colorectal cancer,[2] hepatocellular carcinoma,[3] and non-small cell carcinoma.[4] Less than 30% of cancer patients respond to immune checkpoint therapy, but treatment with Opdivo plus Yervoy at an optimum dosage ratio of 3:1 enhances antitumor efficacy.

Nov 18, 2024 | onlinelibrary.wiley.com | Hongyu Chu |Yanni Li |Hui Yang |Yuhang LIU

European Association for the Study of the Liver. Electronic Address: [email protected], European Association for the Study of the LiverEASL Clinical Practice Guidelines: The Diagnosis and Management of Patients With Primary Biliary Cholangitis

Jul 19, 2023 | frontiersin.org | Ao Zhang |Liang Zhang |Hongyu Chu

1Department of Neurology, The First Hospital of Jilin University, Changchun, China 2Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China 3Department of Neurology, Stroke Center, The First Hospital of Jilin University, Changchun, China 4Department of Neurosurgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China 5Clinical College, Jilin...